AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12208924 — intervention group
Group type: COMPARATOR
Intervention: Anatomic stem (stiff stem with a porous coating)
Number of subjects: 68
Study 31631177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory laparoscopic cholecystectomy (ALC)
Number of subjects: 71
Study 31631177 — intervention group
Group type: COMPARATOR
Intervention: Usual laparoscopic cholecystectomy (ULC)
Number of subjects: 71
Study 29054679 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional method using a custom tray border moulded with impression compound and silicone
Number of subjects: 27
Study 29054679 — intervention group
Group type: COMPARATOR
Intervention: Simplified method using a stock tray and alginate
Number of subjects: 27
Study 29054679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 27
Study 27261067 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 4193
Study 27261067 — intervention group
Group type: COMPARATOR
Intervention: Quadrivalent meningococcal vaccine
Number of subjects: 4193
Study 24752177 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz/lamivudine/zidovudine
Number of subjects: 270
Study 24752177 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz/emtricitabine/tenofovir-DF
Number of subjects: 270
Study 24752177 — intervention group
Group type: COMPARATOR
Intervention: atazanavir/emtricitabine/didanosine-EC
Number of subjects: 270
Study 22297667 — intervention group
Group type: EXPERIMENTAL
Intervention: Better Care system with IEE score cutoff point set at 42%
Number of subjects: 8
Study 22297667 — intervention group
Group type: COMPARATOR
Intervention: Better Care system compared with electrical activity of the diaphragm (EAdi)
Number of subjects: 8
Study 20461767 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue spray applied to the axillary fossa plus placement of closed suction drainage
Number of subjects: 159
Study 20461767 — intervention group
Group type: COMPARATOR
Intervention: Placement of closed suction drainage only
Number of subjects: 159
Study 18991123 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram treatment with remission of maternal depression
Number of subjects: 114
Study 16148999 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical adhesive products applied to retroperitoneal regions (Group A)
Number of subjects: 70
Study 16148999 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 70
Study 12195637 — intervention group
Group type: EXPERIMENTAL
Intervention: Health promotion plus occupational health and safety intervention (HP/OHS)
Number of subjects: 9019
Study 12195637 — intervention group
Group type: COMPARATOR
Intervention: Health promotion (HP)
Number of subjects: 9019
Study 9485226 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 20 ppm (n = 6)
Number of subjects: 11
Study 9485226 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen (n = 5)
Number of subjects: 11
Study 7649143 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-pack cool vest
Number of subjects: 12
Study 7649143 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-pack cool vest
Number of subjects: 12
Study 7649143 — intervention group
Group type: COMPARATOR
Intervention: Control (no cool vest)
Number of subjects: 12
Study 2801583 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diet
Number of subjects: 11
Study 2801583 — intervention group
Group type: COMPARATOR
Intervention: Casein diet
Number of subjects: 11
Study 418546 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluorothymidine (TFT)
Number of subjects: 33
Study 418546 — intervention group
Group type: COMPARATOR
Intervention: Idoxuridine (IDU)
Number of subjects: 33
Study 418546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IDU and TFT
Number of subjects: 33
Study 31268469 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval endurance training (3 times a week for 45 minutes)
Number of subjects: 50
Study 31268469 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (3 times a week for 45 minutes)
Number of subjects: 50
Study 31268469 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 50
Study 28584189 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counselling and SMS reminders (3 sessions over 16 weeks)
Number of subjects: 150
Study 28584189 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 150
Study 28584189 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counselling and SMS reminders
Number of subjects: 150
Study 25734525 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory training for 8 weeks
Number of subjects: 4
Study 25734525 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading training for 8 weeks
Number of subjects: 4
Study 23902482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation
Number of subjects: 400
Study 23902482 — intervention group
Group type: COMPARATOR
Intervention: Nonprotective ventilation
Number of subjects: 400
Study 21798883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sifalimumab (0.3, 1, 3, 10 or 30 mg/kg)
Number of subjects: 50
Study 21798883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19341576 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver diammine fluoride (SDF)
Number of subjects: 66
Study 19341576 — intervention group
Group type: COMPARATOR
Intervention: Cross tooth‐brushing technique (CTT)
Number of subjects: 66
Study 19341576 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer fissure sealant (GIC)
Number of subjects: 66
Study 16868501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 514
Study 16868501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 14726777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored training with a booster after 30 days
Number of subjects: 1325
Study 14726777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored training with boosters at 30 and 90 days
Number of subjects: 1325
Study 14726777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontailored predictor-based training with boosters
Number of subjects: 1325
Study 14726777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no boosters)
Number of subjects: 1325
Study 11737409 — intervention group
Group type: EXPERIMENTAL
Intervention: p24‐VLP 500 microg
Number of subjects: 304
Study 11737409 — intervention group
Group type: EXPERIMENTAL
Intervention: p24‐VLP 1000 microg
Number of subjects: 304
Study 11737409 — intervention group
Group type: COMPARATOR
Intervention: alum placebo
Number of subjects: 304
Study 9403144 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependent women
Number of subjects: 80
Study 9403144 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-critical women
Number of subjects: 80
Study 8433832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent monitoring
Number of subjects: 169
Study 8433832 — intervention group
Group type: COMPARATOR
Intervention: Continuous monitoring
Number of subjects: 169
Study 3618273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolipram
Number of subjects: 21
Study 3618273 — intervention group
Group type: COMPARATOR
Intervention: Desipramine
Number of subjects: 21
Study 29081219 — intervention group
Group type: EXPERIMENTAL
Intervention: mPLN > 3
Number of subjects: 249
Study 29081219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphovascular invasion (LVI)
Number of subjects: 249
Study 29081219 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-squamous cell carcinoma (non-SqCC)
Number of subjects: 249
Study 29081219 — intervention group
Group type: COMPARATOR
Intervention: mPLN ≤ 3
Number of subjects: 249
Study 29081219 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring system using mPLNs > 3, LVI, and non-SqCC
Number of subjects: 249
Study 27369028 — intervention group
Group type: EXPERIMENTAL
Intervention: Online learning module on FPDR
Number of subjects: 74
Study 27369028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no online learning)
Number of subjects: 74
Study 25179088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthwash solution containing lysine (0.4%) and glycerol monolaurate (0.2%) (LGM)
Number of subjects: 277
Study 25179088 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment for gastric eradication
Number of subjects: 277
Study 25179088 — intervention group
Group type: COMPARATOR
Intervention: Traditional drug gastric eradication and teeth cleaning (TC)
Number of subjects: 277
Study 25179088 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of oral infection
Number of subjects: 277
Study 22437920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ablation (EA)
Number of subjects: 217
Study 19944517 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 50
Study 19944517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18155448 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic stressor (2DG)
Number of subjects: 44
Study 18155448 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study 18155448 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 44
Study 15329742 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HC)
Number of subjects: 34
Study 15329742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12610676 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 12610676 — intervention group
Group type: COMPARATOR
Intervention: Risk stratification tools
Number of subjects: 0
Study 10586152 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent hydrocolloid dressing
Number of subjects: 132
Study 10586152 — intervention group
Group type: COMPARATOR
Intervention: Standard polyurethane dressing
Number of subjects: 132
Study 8607501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily plus metronidazole 250 mg four times daily
Number of subjects: 41
Study 8607501 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone 0.7 mg/kg/day with variable tapering to 40 mg
Number of subjects: 41
Study 8607501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus metronidazole
Number of subjects: 41
Study 8607501 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 41
Study 2012458 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour nicotine delivery
Number of subjects: 158
Study 2012458 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine delivery during wakeful hours only
Number of subjects: 158
Study 2012458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 2012458 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 158
Study 6129858 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam (Frisium 20) administered in the morning for 28 days
Number of subjects: 60
Study 6129858 — intervention group
Group type: COMPARATOR
Intervention: Clobazam (Frisium 20) administered at night for 28 days
Number of subjects: 60
Study 30629474 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-continuous training (CONT)
Number of subjects: 28
Study 30629474 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (INT)
Number of subjects: 28
Study 30629474 — intervention group
Group type: COMPARATOR
Intervention: CONT
Number of subjects: 28
Study 30629474 — intervention group
Group type: COMPARATOR
Intervention: INT
Number of subjects: 28
Study 30629474 — intervention group
Group type: COMPARATOR
Intervention: Both CONT and INT
Number of subjects: 28
Study 29460049 — intervention group
Group type: EXPERIMENTAL
Intervention: Blom Singer Low Pressure
Number of subjects: 0
Study 29460049 — intervention group
Group type: EXPERIMENTAL
Intervention: Blom Singer Classic Indwelling
Number of subjects: 0
Study 29460049 — intervention group
Group type: EXPERIMENTAL
Intervention: Provox Vega
Number of subjects: 0
Study 29460049 — intervention group
Group type: COMPARATOR
Intervention: Patient self-evaluation
Number of subjects: 0
Study 29460049 — intervention group
Group type: COMPARATOR
Intervention: Experts' choice
Number of subjects: 0
Study 27071768 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide 30 or 60 µg
Number of subjects: 1251
Study 27071768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1251
Study 24501005 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV 90 mg QD for 24 weeks
Number of subjects: 140
Study 24501005 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV 90 mg QD for 12 weeks
Number of subjects: 140
Study 24501005 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV 30 mg QD for 24 weeks
Number of subjects: 140
Study 24501005 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV 90 mg QD for 12 weeks in patients with vRVR
Number of subjects: 140
Study 24501005 — intervention group
Group type: EXPERIMENTAL
Intervention: LDV 90 mg QD for 24 weeks in patients with vRVR
Number of subjects: 140
Study 21822978 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin plus octreotide combination treatment post-TACE
Number of subjects: 147
Study 21822978 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin plus octreotide treatment)
Number of subjects: 147
Study 17931721 — intervention group
Group type: EXPERIMENTAL
Intervention: 40,000 IU Epo
Number of subjects: 51
Study 17150024 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab monotherapy 300 mg intravenous every 4 weeks
Number of subjects: 0
Study 17150024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15167852 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bupivacaine
Number of subjects: 63
Study 15167852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 11558012 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 43
Study 11558012 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 43
Study 9663954 — intervention group
Group type: EXPERIMENTAL
Intervention: Short muscle length (bout S)
Number of subjects: 7
Study 9663954 — intervention group
Group type: EXPERIMENTAL
Intervention: Long muscle length (bout L)
Number of subjects: 7
Study 9663954 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 7
Study 8143451 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 2
Study 8143451 — intervention group
Group type: COMPARATOR
Intervention: Progesterone 100 mg
Number of subjects: 2
Study 8143451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 3276280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine (average dose, 40 mg/d)
Number of subjects: 16
Study 3276280 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (average dose, 820 mg/d)
Number of subjects: 16
Study 3276280 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluoperazine (average dose, 7.8 mg/d)
Number of subjects: 16
Study 3276280 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (average dose, 4.7 mg/d)
Number of subjects: 16
Study 3276280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1827023 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isradipine (0.5 mg, n = 10)
Number of subjects: 21
Study 1827023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 21
Study 793779 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (1 mg to 3 mg daily)
Number of subjects: 20
Study 793779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 793779 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (equipotent doses)
Number of subjects: 20
Study 31916428 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural extracted tooth as a coronal seal
Number of subjects: 12
Study 31916428 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional resin preformed as a seal technique
Number of subjects: 12
Study 31916428 — intervention group
Group type: COMPARATOR
Intervention: Control group 1: extraction socket left with blood clot and interrupted sutures
Number of subjects: 12
Study 31916428 — intervention group
Group type: COMPARATOR
Intervention: Control group 2: extraction socket filled with BioOss Collagen and free gingival graft
Number of subjects: 12
Study 31916428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tx 1 group
Number of subjects: 12
Study 31916428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tx 2 group
Number of subjects: 12
Study 31916428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tx 3 group
Number of subjects: 12
Study 31916428 — intervention group
Group type: EXPERIMENTAL
Intervention: Tx 4 group
Number of subjects: 12
Study 28392215 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene care programme (AOHCP) comprising a powered toothbrush, 0.2% chlorhexidine mouthrinse, toothpaste, and oral hygiene instruction
Number of subjects: 0
Study 28392215 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral hygiene care programme (COHCP) comprising a manual toothbrush, toothpaste, and oral hygiene instruction
Number of subjects: 0
Study 25840580 — intervention group
Group type: EXPERIMENTAL
Intervention: Carperitide infusion
Number of subjects: 668
Study 25840580 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 668
Study 23982402 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportal (TP) technique
Number of subjects: 80
Study 23982402 — intervention group
Group type: COMPARATOR
Intervention: Outside-in (OI) technique
Number of subjects: 80
Study 21863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorder presence
Number of subjects: 0
Study 21863207 — intervention group
Group type: COMPARATOR
Intervention: Case manager identification of anxiety disorder
Number of subjects: 0
Study 21863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Locus of control
Number of subjects: 0
Study 21863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal thinking
Number of subjects: 0
Study 21863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotic symptoms
Number of subjects: 0
Study 21863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 0
Study 21863207 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of substance dependence
Number of subjects: 0
Study 19539926 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2
Number of subjects: 0
Study 19539926 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 17258568 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 116
Study 17258568 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 116
Study 16287365 — intervention group
Group type: EXPERIMENTAL
Intervention: Runners Advantage (RA) creatine serum (5 ml containing 2.5 g of Cr)
Number of subjects: 24
Study 16287365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study 11348602 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/day
Number of subjects: 1750
Study 9322568 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene (90 mg/d for 3 weeks)
Number of subjects: 0
Study 9322568 — intervention group
Group type: COMPARATOR
Intervention: Beta-carotene (50 mg every other day for 10-12 years)
Number of subjects: 0
Study 9322568 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (short- and long-term)
Number of subjects: 0
Study 7945032 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial keratotomy
Number of subjects: 427
Study 3224091 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 9
Study 3224091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31797549 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla-300
Number of subjects: 604
Study 31797549 — intervention group
Group type: COMPARATOR
Intervention: Gla-100
Number of subjects: 604
Study 29436740 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget transcranial direct current stimulation (primary motor cortex and left dorsolateral prefrontal cortex)
Number of subjects: 20
Study 29436740 — intervention group
Group type: COMPARATOR
Intervention: Primary motor cortex only
Number of subjects: 20
Study 29436740 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 28068170 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4501
Study 28068170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4501
Study 28068170 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane and Placebo (overall)
Number of subjects: 4501
Study 26028456 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAN intervention (nurse-led outpatient counselling, transitional guidance, routine symptom assessment, patient counselling)
Number of subjects: 370
Study 26028456 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 370
Study 26028456 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAN intervention
Number of subjects: 370
Study 23981710 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff training intervention (manualised programme comprising three phases: predisposing, enabling, and reinforcing)
Number of subjects: 40
Study 23981710 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 22176946 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual targets
Number of subjects: 31
Study 22176946 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic targets
Number of subjects: 31
Study 22176946 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisaccade condition
Number of subjects: 31
Study 19917951 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text-message reminders for 6 weeks
Number of subjects: 70
Study 19917951 — intervention group
Group type: COMPARATOR
Intervention: No text-message reminders
Number of subjects: 70